[{"id":"65e8d7c8-cd05-4be4-b31d-3d804c0d4afd","acronym":"NCI-2009-01173","url":"https://clinicaltrials.gov/study/NCT00843882","created_at":"2023-11-21T16:15:34.542Z","updated_at":"2025-02-25T16:43:32.520Z","phase":"Phase 3","brief_title":"Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia","source_id_and_acronym":"NCT00843882 - NCI-2009-01173","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTPRC • CDC25C • GNRP","pipe":"","alterations":" ","tags":["PTPRC • CDC25C • GNRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Retacrit (epoetin alfa-epbx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 01/29/2009","start_date":" 01/29/2009","primary_txt":" Primary completion: 07/08/2019","primary_completion_date":" 07/08/2019","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2025-02-06"}]